Leaders in Pharmaceutical Business Intelligence (LPBI) Group

11:00 am – 12:00 pm, 3/27/2015 Defining Value @ MassBio Annual Meeting 2015, Cambridge, MA, Sonesta Hotel, 3/26 – 3/27, 2015

Reporter: Aviva Lev-Ari, PhD, RN

Dr. Aviva Lev-Ari will be in attendance on March 26, 2015, 8:00AM to March 27, 2015, 2:00PM

Leaders in Pharmaceutical Business Intelligence are Covering the Event in REALTIME using Social Media

http://pharmaceuticalintelligence.com

Panelists:

• Sarah Emond, Chief Operating Officer, lnstitute for Clinical and Economic Review

1. Quality and Value – comparative studies on Value in Public sphere
2. Vested interest in the conversation of demonstration of value, pay for product and the Patient
3. How the Healthcare is spent – value of drugs  by eligibility, Oncology Patient is a very large patient population
4. How the drug fits in the entire system not only
5. Decisions that Patients need to make decision with their healthcare cost — deductable of $5,000 – causes patient to take more ownership over the decision on what to spend the money on alternative treatments
6. Stakeholders, Medical societies, Total spending interventions and diagnostics
7. transperancies on Waht is Value of Clinical Effectiveness
8. manufacturers need to understand Cost per treatment, Insurance of a Health plan need to cover
9. A company needs to pay for innovation
10. European model vs US Model
11. Access to treatment, decisions needed transparency since there is an allocation in distribution of budgets in Europe

• Christopher Hansen, President, American Cancer Society Cancer Action Network, Inc.

(Ex-Boeing Exec VP, Ex- Electronics Society, MIT grad)

1. Patient interest
2. Pricing Drugs in comparison with other drugs for the value that each is delivering vs. paying the premium to justify the price
3. value proposition of drugs – oncology drugs
4. Personalized – companies transitioned from very admired to disliked comapnies as it is related to a product price, negative perception of an industry
5. Companies like Boeing need to care to be an admired company, PBS was invited to all meeting of the development of an aircraft

• Glenn Batchelder, MassBio, Chair Board of Directors

1. Access to drugs that are in the pipeline
2. 90,000 American will die in 2015 from Cancer – we know drugs for Lung Cancer
3. Obesity  as cause of comorbidity and shorter life expectancy
4. Basic Research by Government funded R&D
5. Healthcare best in the World in the US, HealthCare System — no system in existence in the US
6. Multiple MODELS can work, Pharma Model: All internally, Biotech early stage – nimble, Biotech in 2015
7. FDA Regulatory – plays a very important perspective: Personalized Medicine
8. COnversation is most important to shape the future of Medicine and of Biotech — facilitation is needed

Moderator:

• William Sibold, Senior Vice President, Head of Multiple Sclerosis, Genzyme

Two MS drugs there are 50 MS drugs to be launched around the World. VALUE is sustainability – Biotech bring value to Patients. Debate on single products:

• Alzheimers’ Disease
• HepC
• The Myeloma Foundation is an example of a great contribution of an organization in engaging Patients in the decision making on Treatment as well as participation in Clinical Trials funded by the Foundation
• Biotech followed Pharma, Biotech had from the beginning the need to be admired by the Patient.
• Co-pay vs Life or death, increase fees, Customer will not buy plans if two expensive. Value proposition is different from the employee and the Employer
• Patient needs advocatess the Healthcare System in the US is very complex
• Interface with Medicine some are knowledgeable other are not
• Cystic Fybrosis Foundation encourages investment
• Google and Apple are entering the Healthcare R&D  – they do not care for returns because their source of return are their core business
• Interest in Big Data in Healthcare and the mining capabilities to inform decision making